If you just got a glioblastoma diagnosis, your pathology report shows whether your tumor is IDH-wildtype or IDH-mutant. This marker is one of the most important pieces of information in your diagnosis. It changes how doctors classify your tumor, predicts how fast it will grow, and tells you whether certain targeted treatments might work for you.
IDH stands for isocitrate dehydrogenase - an enzyme that helps cells make energy. When a gene that codes for this enzyme has a mutation, the tumor cell's metabolism changes in an abnormal way. Whether or not that mutation is present divides brain tumors into two distinct groups, even when they look similar under the microscope.
What Does IDH Status Mean in Glioblastoma?
IDH status tells you whether the tumor has a mutation in the IDH1 or IDH2 gene. IDH-wildtype means the gene is normal. IDH-mutant means one of these genes has an alteration that changes how the tumor cell processes energy. According to the National Brain Tumor Society, this distinction is now central to how doctors classify brain tumors under the 2021 World Health Organization (WHO) system - the framework that all major brain tumor centers use.
IDH-wildtype tumors account for roughly 90% of all glioblastomas. They usually appear in older adults, grow rapidly, and have a shorter expected survival compared to IDH-mutant tumors. Doctors previously sometimes called IDH-mutant tumors glioblastoma, but the 2021 WHO classification no longer uses that name for IDH-mutant tumors. Under the current system, an IDH-mutant tumor that reaches grade 4 is now called astrocytoma, IDH-mutant, grade 4 - not glioblastoma. True glioblastoma, by current definition, is IDH-wildtype.
How the 2021 WHO Classification Changed the Definition of Glioblastoma
Before 2021, pathologists could diagnose glioblastoma, IDH-mutant or glioblastoma, IDH-wildtype. Both had the same name despite very different biology, which created real confusion. The cIMPACT-NOW working group - an international panel that advises on brain tumor classification - recommended separating these groups. The 2021 WHO classification adopted that recommendation.
Today, glioblastoma refers exclusively to IDH-wildtype tumors. Doctors classify an IDH-wildtype diffuse glioma as WHO grade 4 glioblastoma if it has at least one of these molecular changes: TERT promoter mutation, EGFR amplification, or a combined gain of chromosome 7 and loss of chromosome 10 (written as +7/-10). These markers signal aggressive tumors even when you don't see features like necrosis or abnormal blood vessel growth under the microscope.
This change matters in practice. If your pathology report says glioblastoma, IDH-mutant, it was written before 2021. You might ask your doctor for a second review using the current WHO system - this is one reason your glioblastoma grade can change after molecular testing, and why that reclassification can change which treatments your team considers.
How Is IDH Status Tested?
Doctors test for IDH in tumor tissue removed during surgery or biopsy. The most common first test is immunohistochemistry (IHC) - a staining technique - that detects the IDH1-R132H mutation, which accounts for most IDH mutations in adults. If that test is negative and the doctor suspects a rarer mutation - especially in a younger patient - they do DNA sequencing of IDH1 and IDH2. Most comprehensive molecular panels now include both tests automatically.
Knowing why molecular testing should happen within the first six weeks after surgery can help you act quickly if your biopsy results are incomplete or were never ordered.
How Do IDH-Wildtype and IDH-Mutant Grade 4 Gliomas Compare?
The table below shows the most clinically relevant differences between the two groups.
| Feature | IDH-Wildtype Glioblastoma | IDH-Mutant Astrocytoma (Grade 4) |
|---|---|---|
| WHO classification | Glioblastoma, IDH-wildtype, grade 4 | Astrocytoma, IDH-mutant, grade 4 |
| Typical age at diagnosis | Median approximately 60-65 years | Median approximately 35-45 years |
| Median overall survival | Approximately 12-16 months with standard treatment; MGMT methylation improves this | Typically longer than IDH-wildtype; varies by CDKN2A/B deletion and MGMT status |
| Defining molecular markers | TERT promoter mutation, EGFR amplification, or +7/-10 chromosomal change | IDH1 or IDH2 mutation; CDKN2A/B deletion elevates to grade 4 |
| MGMT methylation relevance | Critical - predicts temozolomide response and overall survival | Relevant, but IDH mutation already provides some baseline chemosensitivity |
| Targeted therapy options | No approved IDH-targeted drug; EGFR and immunotherapy trials ongoing | Vorasidenib (FDA-approved 2024 for grade 2-3; grade 4 role under study in trials) |
Sources: NCDB analysis of IDH-wildtype GBM outcomes by MGMT methylation status, 2025; National Brain Tumor Society - 2021 WHO classification update.
The biggest difference is prognosis. IDH-wildtype glioblastoma has a shorter expected survival than IDH-mutant grade 4 astrocytoma. Within IDH-wildtype GBM, MGMT methylation status matters - methylated cases tend to survive longer on average. Within IDH-mutant grade 4 tumors, the CDKN2A/B deletion (a tumor suppressor gene loss) is what raises the grade from 2-3 to 4 and worsens outlook compared to lower-grade IDH-mutant disease.
How IDH-Wildtype Status Shapes Your Treatment Plan
For IDH-wildtype glioblastoma, the current standard treatment is the Stupp protocol: surgery to remove as much tumor as safely possible, followed by radiation combined with temozolomide chemotherapy, then six cycles of maintenance temozolomide. Tumor Treating Fields (Optune) - a wearable device that uses low-intensity electric fields to disrupt tumor cells - may be added with maintenance chemotherapy for patients in good health.
Within IDH-wildtype GBM, your MGMT methylation result matters most after IDH status. A large analysis of U.S. National Cancer Database patients found that MGMT-methylated IDH-wildtype GBM had a median overall survival of approximately 16.4 months, compared with approximately 11.8 months in MGMT-unmethylated cases. MGMT methylation means the tumor has less ability to repair the DNA damage that temozolomide causes, making the drug more effective.
If your tumor is IDH-wildtype with unmethylated MGMT, your oncologist might suggest adding lomustine (another chemotherapy) or enrolling in a clinical trial. Current chemotherapy strategies for IDH-wildtype glioblastoma show that no targeted therapy has been approved specifically for IDH-wildtype tumors. Researchers are actively studying bevacizumab, immunotherapy combinations, and tumor-specific vaccine approaches in trials. Getting a second opinion from a brain tumor specialist is especially important in this scenario, since the standard protocol usually won't produce a long response in unmethylated cases.
How IDH-Mutant Status Opens Targeted Therapy Options
IDH-mutant grade 4 astrocytoma follows a similar broad framework - surgery, radiation, and temozolomide-based chemotherapy. But the IDH mutation itself is now a direct treatment target. Vorasidenib, an oral IDH1/IDH2 inhibitor that crosses the blood-brain barrier, received U.S. FDA approval in August 2024 for adults with IDH-mutant grade 2 or 3 gliomas after surgery. The pivotal INDIGO trial, published in The New England Journal of Medicine, found that vorasidenib improved median progression-free survival to 27.7 months compared with 11.1 months for placebo in IDH-mutant grade 2-3 gliomas.
Researchers are still studying whether vorasidenib will help IDH-mutant grade 4 astrocytoma. The important point is that if your tumor is IDH-mutant, your molecular profile opens a treatment option that does not exist for IDH-wildtype GBM patients. Getting a thorough molecular panel reviewed by a specialist matters. If you want a structured review of your IDH status and broader molecular profile to understand which trials or precision options may apply, you can explore precision-oncology options through Art of Healing Cancer.
IDH-mutant tumors may also carry the 1p/19q codeletion - a chromosomal change that, when present with IDH mutation, defines oligodendroglioma rather than astrocytoma. Oligodendroglioma has a distinctly different prognosis and treatment response. The article on why grade 3 oligodendroglioma has a better prognosis than GBM explains how these diagnoses differ in practice.
What Other Molecular Markers Appear on Your Report?
IDH status rarely appears alone. Your pathology report may also show results for EGFR amplification, PTEN loss, TERT promoter mutation, and MGMT methylation. For IDH-wildtype GBM, EGFR amplification means you might be a candidate for EGFR-targeted therapies currently in clinical trials. PTEN loss - found in many IDH-wildtype GBMs - links to reduced chemotherapy response and is a growing focus in precision-oncology protocols. Research into biomarkers that distinguish IDH-wildtype from IDH-mutant GBM continues to expand what doctors can learn from each subtype, which is why reviewing the full molecular panel - not just IDH status - with a specialist matters.
Should You Request a Molecular Review if Your IDH Result Is Unclear?
Some patients get an initial report that is ambiguous - for example, a tumor classified as IDH-wildtype based on IHC staining alone, without full DNA sequencing. In younger patients (under 55 years), the chance of carrying a rarer IDH mutation is higher, and full sequencing can change the classification and treatment plan. If your report doesn't say which IDH testing method was used, or if EGFR and TERT analysis weren't done alongside IDH testing, asking for a more complete molecular review makes sense.
Getting a pathology report that feels incomplete is stressful when you're already under pressure to start treatment. In most cases, taking a few days to have your molecular results reviewed by a specialist won't delay your treatment and can help your team pick the best protocol from the start.
When to Talk to Your Doctor
Talk to your neuro-oncologist if your pathology report doesn't include IDH testing results, if your report used pre-2021 naming and might need reclassification, if you are IDH-mutant and want to know whether vorasidenib or an IDH-inhibitor trial applies to your grade, or if your tumor is IDH-wildtype with unmethylated MGMT and you want to know what options exist beyond the standard protocol. A molecular tumor board review - available at major neuro-oncology centers and through remote consultation - is worth requesting before you commit to a treatment plan. You can start by uploading your MRI and pathology reports for a remote review to understand what your molecular subtype means for your treatment options.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.